Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Aktis Oncology, Inc.NASDAQ: AKTS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation of $3.02M in Q1 FY2026
Q1 FY2026 stock-based compensation was $3.02M. Over 3 fiscal years it compounded at +94.4% a year.
Context
- Stock-based compensation amounted to 79.0% of revenue in FY2025, down 73.0 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 5.13M USD
- Year-over-year change
- +127.0%
- 3-year CAGR
- +94.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.13M | +127.0% |
| FY2024 | 2024-12-31 | 2.26M | +52.9% |
| FY2023 | 2023-12-31 | 1.48M | +111.7% |
| FY2022 | 2022-12-31 | 698K | — |
Stock-Based Compensation vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's FY2025 stock-based compensation of $5.13M is the 5th largest of the 6 companies compared; the peer median is $14.63M.
- Its year-over-year change of +127.0% is the highest of 6, against a peer median of +14.1%.
- Stock-based compensation amounts to 79.0% of revenue for AKTS, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $37.41M | +60.8% | +68.9% | — | |
| LTM Mar 2026 | $28.21M | +14.1% | — | 7.3% | |
| LTM Mar 2026 | $14.63M | +18.7% | +30.7% | — | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| FY2025 | $5.13M | +127.0% | +94.4% | 79.0% | |
| LTM Mar 2026 | $2.68M | -107.0% | +13.8% | 4.2% | |
| Peer median (excluding AKTS) | $14.63M | +14.1% | +22.3% | 7.3% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Depreciation & Amortization | 445K | 1.12M | 1.58M | 2.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 698K | 1.48M | 2.26M | 5.13M |
| Change in Working Capital | (1.14M) | (15K) | 58.98M | (3.23M) |
| Accounts Receivables | 0 | (257K) | (861K) | 1.03M |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | (1K) | 659K | 360K | (44K) |
| Other Working Capital | (1.14M) | (417K) | 59.48M | (4.22M) |
| Other Non-Cash Items | (200K) | (3.95M) | (4.07M) | (4.62M) |
| Operating Cash Flow | (18.13M) | (30M) | 14.76M | (64.13M) |
| Capital Expenditures | (2.31M) | (3.76M) | (2.86M) | (9.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (145.81M) | (288.4M) | (193.87M) |
| Sales of Investments | 0 | 80.69M | 100.86M | 269.42M |
| Other Investing Activities | 0 | 57K | 0 | 0 |
| Investing Cash Flow | (2.31M) | (68.83M) | (190.4M) | 65.96M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 336K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (151K) | 0 | (1.72M) | (1.55M) |
| Financing Cash Flow | 119.98M | 0 | 183.28M | (1.21M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 99.55M | (98.83M) | 7.65M | 625K |
| Free Cash Flow | (20.43M) | (33.77M) | 11.9M | (73.71M) |
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.